Libtayo
Libtayo Approved for Previously Treated Basal Cell Carcinoma
The FDA granted cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) approval for treatment of patients with locally ...
FEBRUARY 17, 2021
FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018
Load more